CN100438881C - 鳄鱼血在制备抗肿瘤抗病毒提高免疫力的药物及保健食品中的应用 - Google Patents
鳄鱼血在制备抗肿瘤抗病毒提高免疫力的药物及保健食品中的应用 Download PDFInfo
- Publication number
- CN100438881C CN100438881C CNB2004100518604A CN200410051860A CN100438881C CN 100438881 C CN100438881 C CN 100438881C CN B2004100518604 A CNB2004100518604 A CN B2004100518604A CN 200410051860 A CN200410051860 A CN 200410051860A CN 100438881 C CN100438881 C CN 100438881C
- Authority
- CN
- China
- Prior art keywords
- crocodile blood
- crocodile
- group
- mice
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000270722 Crocodylidae Species 0.000 title claims abstract description 55
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 title claims abstract description 54
- 210000004369 blood Anatomy 0.000 title claims abstract description 32
- 239000008280 blood Substances 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 230000036039 immunity Effects 0.000 title claims abstract description 14
- 235000013305 food Nutrition 0.000 title abstract 3
- 230000036541 health Effects 0.000 title description 4
- 230000001093 anti-cancer Effects 0.000 title 1
- 230000002155 anti-virotic effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 230000000840 anti-viral effect Effects 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- 241000700605 Viruses Species 0.000 abstract description 14
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 230000000531 effect on virus Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 239000008176 lyophilized powder Substances 0.000 description 23
- 210000002381 plasma Anatomy 0.000 description 22
- 230000037396 body weight Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000002002 slurry Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000007501 Thymosin Human genes 0.000 description 3
- 108010046075 Thymosin Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229940084983 cyclophosphamide 50 mg Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 230000003067 hemagglutinative effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100518604A CN100438881C (zh) | 2004-10-19 | 2004-10-19 | 鳄鱼血在制备抗肿瘤抗病毒提高免疫力的药物及保健食品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100518604A CN100438881C (zh) | 2004-10-19 | 2004-10-19 | 鳄鱼血在制备抗肿瘤抗病毒提高免疫力的药物及保健食品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634147A CN1634147A (zh) | 2005-07-06 |
CN100438881C true CN100438881C (zh) | 2008-12-03 |
Family
ID=34846087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100518604A Active CN100438881C (zh) | 2004-10-19 | 2004-10-19 | 鳄鱼血在制备抗肿瘤抗病毒提高免疫力的药物及保健食品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100438881C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10195230B2 (en) * | 2006-12-14 | 2019-02-05 | Mcneese State University | Blood product from crocodylian species as a feed supplement for weanling pigs and poultry hatchlings |
CN102217754B (zh) * | 2011-03-07 | 2012-08-29 | 陈献君 | 一种鳄鱼血米粉末的制作方法 |
CN102268090B (zh) * | 2011-07-13 | 2014-12-10 | 北京洪源澳达生物技术发展有限公司 | 一种暹罗鳄血液提取物及其提取方法和用途 |
CN105147720B (zh) * | 2015-10-26 | 2019-01-18 | 百生康(北京)健康产业科技有限公司 | 鳄鱼血多糖在肝癌治疗中的应用 |
CN107198010A (zh) * | 2017-06-20 | 2017-09-26 | 慧谷生命科技湖北有限公司 | 一种鳄鱼血压片糖果 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1383889A (zh) * | 2001-04-27 | 2002-12-11 | 关令华 | 鳄鱼丸 |
CN1465351A (zh) * | 2002-06-26 | 2004-01-07 | 关令华 | 鳄鱼免疫抗癌丸 |
-
2004
- 2004-10-19 CN CNB2004100518604A patent/CN100438881C/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1383889A (zh) * | 2001-04-27 | 2002-12-11 | 关令华 | 鳄鱼丸 |
CN1465351A (zh) * | 2002-06-26 | 2004-01-07 | 关令华 | 鳄鱼免疫抗癌丸 |
Also Published As
Publication number | Publication date |
---|---|
CN1634147A (zh) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101512495B1 (ko) | 혈구 감소 관련 질환 예방 및 치료용 약물을 제조하기 위한 악티게닌의 용도 | |
CN104510747B (zh) | 一种环烯醚萜苷的药物新用途 | |
JP2017516854A (ja) | 抗腫瘍相乗減毒効果を有する薬用溶液及びそれを含む薬用組成物 | |
CN100438881C (zh) | 鳄鱼血在制备抗肿瘤抗病毒提高免疫力的药物及保健食品中的应用 | |
CN106309455B (zh) | 贝母辛的用途 | |
CN109793727A (zh) | 一种有效抗恶性肿瘤的药物组合物及其应用 | |
CN111803484B (zh) | 奥替溴铵在制备抗肿瘤药物中的应用 | |
CN102232957B (zh) | 3-乙酰氧基-8,24-羊毛甾二烯-21-酸在制备预防、治疗肝癌或乳腺癌药物中的用途 | |
CN104666320A (zh) | 曲札茋苷在制备治疗癌症药物中的应用 | |
CN104688722B (zh) | 淫羊藿苷元在制备预防或治疗骨髓抑制药物中的用途 | |
CN106377537B (zh) | 乙酰黄芪苷的应用 | |
CN103599111B (zh) | 用于治疗胰腺癌的组合药物 | |
CN108836975B (zh) | 野蔷薇苷的新应用 | |
CN110354121A (zh) | 环吡酮胺在制备***药物中的应用和包含环吡酮胺的组合药物及用途 | |
CN103169693A (zh) | 汉黄芩素衍生物在制备治疗肝癌的药物中的应用 | |
CN110327317A (zh) | 紫草素在制备抗轮状病毒感染的药物中的应用 | |
CN113616654B (zh) | Gsk872在制备治疗肠道病毒71型感染导致的疾病的药物中的用途 | |
CN109953999B (zh) | 由灵芝多糖、猪苓多糖组成的具有免疫增强作用的组合物 | |
TW200412989A (en) | Gamma delta T cell immunoactivity enhancers containing extract of Lentinus edodes mycelium | |
CN117045639B (zh) | 一种用于治疗胃癌的药物组合物及其应用 | |
CN106727495B (zh) | 一类二氢黄酮化合物在制备心肌保护药物中的应用 | |
CN102327287A (zh) | 河马血在制备抗肿瘤药物中的应用 | |
CN104873513B (zh) | 一种抑制肺癌细胞转移的药物组合物以及检测方法 | |
CN106074565B (zh) | 一种含索拉菲尼和小分子化合物的药物组合物及其在制备抗肿瘤药物中的应用 | |
CN111904957A (zh) | 奥昔卡因在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240307 Address after: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee after: Chengdu yishenrui Technology Co.,Ltd. Country or region after: Zhong Guo Address before: 510275 School of pharmacy, Zhongshan University, 135 West Xingang Road, Guangzhou, Guangdong Patentee before: SUN YAT-SEN University Country or region before: Zhong Guo |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240319 Address after: No. 5-4 Xihu Street, Yuhong District, Shenyang City, Liaoning Province, 110000 (1-6-1) Patentee after: Shenyang Yufeng Life Technology Co.,Ltd. Country or region after: Zhong Guo Address before: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee before: Chengdu yishenrui Technology Co.,Ltd. Country or region before: Zhong Guo |
|
TR01 | Transfer of patent right |